Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: formula (1) or physiologically acceptable salt thereof [structure]

Claims

25 · 3 independent · depth 6

25 granted claims

›1.independentA compound having the formula:+9

›2.↳ 1The compound of claim 1 wherein Ring A is unsubstituted and B is substituted para to the carbon atom of ring B that is bonded to X1 in ring C, and Z i…d2+7

›3.↳ 2The compound of claim 2 whereinnR1 is â€”H or â€”OH; andR2 is substituted aromatic group, wherein said substituted aromatic group is 4-halophenyl.d3+3

›7.↳ 2The compound of claim 2 wherein at least one of R70, R71, R72 and R73 is an aliphatic group or a substituted aliphatic group; whereinnsaid aliphatic g…d3+2

›10.↳ 1A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 and a physiologically acceptable carrier…d2

›11.independentA compound having the formula:+7

›18.independentA compound having the structure:+6

Classifications

12 codes

IPC · International Patent Classification

Section A — Human necessities

A01N43/42
A61K31/44

Section C — Chemistry; metallurgy

C07D453/00
C07D451/00
C07D401/00

USPC · US Patent Classification

514/291546/80546/18546/81546/20546/93546/89

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

Pendency

4.3 y

1,574 days filing → grant

Office actions

after a restriction

Responses

1 RCE

Examiner

Niloofar Rahmani

art unit —

Law firm

Law firm · Log in to unlock

Citations: 151 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Priority chain

1 priority documents

›Priority documents — 1

Type	Document	Date
related publication	US 20050070549 A1	31 Mar 2005

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.